07 Nov European School of Oncology: Treatment for early stage ILC
The European School of Oncology (ESO) offered an e-learning session on November 10, 2018 focusing on treatment of early-stage lobular breast cancer.
The session entitled Treatment of Early-Stage Invasive Lobular Carcinoma featured expert and LBCA Scientific Advisory board member Otto Metzger, MD of the Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute and Harvard Medical School in Boston.
This 45 minute online presentation with slides is designed for clinicians, medical professionals and oncologists, and includes the following key points:
• The challenge of subgroup analysis
• The role of adjuvant chemotherapy
• Recommendations for adjuvant endocrine therapy
• Special subsets of ILC
The educational session offers an overview of lobular breast cancer, a discussion about subgroup analysis and presents information on use of chemotherapy and endocrine therapies (for example Tamoxifen or and Aromatase Inhibitor) in treating early stage patients with ILC. It also discusses subsets of patients with HER2+ mutations.